A Phase Ib/II Clinical Trial of LBL-007 Combined With Tislelizumab in the Treatment of Malignant Tumors

Clinical trial NCT05516914 · COMPLETED

Trial details

NCT number: NCT05516914
Sponsor: Nanjing Leads Biolabs Co.,Ltd
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Malignant Tumors

Start date: 2022-09-01
Primary completion: 2026-01-30
Enrollment: 98

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.